Tonix Pharmaceuticals Holding Corp. (TNXP) closed at $3.24 on November 12, 2026, down 16.3% from the previous close, on volume of 2,378,589 shares (30-day average 1,024,349).
Data as of November 12, 2026.
TipRanks (Tue, 10-Nov 1:00 AM ET)
Tonix Pharmaceuticals Earnings Call Highlights TONMYA Growth
TipRanks (Mon, 9-Nov 7:02 PM ET)
Tonix Pharmaceuticals GAAP EPS of -$2.89 misses by $0.50, revenue of $17.23M beats by $0.91M
Seeking Alpha News (Mon, 9-Nov 7:10 AM ET)
Tonix Pharmaceuticals Reports Third Quarter 2026 Financial Results and Operational Highlights
Globe Newswire (Mon, 9-Nov 7:00 AM ET)
Here are the major earnings before the open Monday
Seeking Alpha News (Sun, 8-Nov 6:04 PM ET)
Tonix Pharmaceuticals to Present at Guggenheim's 3rd Annual Healthcare Innovation Conference
Globe Newswire (Wed, 4-Nov 7:00 AM ET)
Globe Newswire (Mon, 2-Nov 7:00 AM ET)
Globe Newswire (Tue, 27-Oct 7:00 AM ET)
Tonix Sets Nov. 9 Call to Detail Q3 2026 Results and Operational Updates
Market Chameleon (Mon, 26-Oct 5:17 AM ET)
Tonix Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 9, 2026
Globe Newswire (Mon, 26-Oct 7:00 AM ET)
Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.
Tonix Pharmaceuticals Holding Corp. trades on the NASDAQ stock market under the symbol TNXP.
As of November 12, 2026, TNXP stock price declined to $3.24 with 2,378,589 million shares trading.
TNXP has a beta of 1.25, meaning it tends to be more sensitive to market movements. TNXP has a correlation of 0.05 to the broad based SPY ETF.
TNXP has a market cap of $62.96 million. This is considered a Micro Cap stock.
Last quarter Tonix Pharmaceuticals Holding Corp. reported $17 million in Revenue and -$2.89 earnings per share. This beat revenue expectation by $946,720 and missed earnings estimates by -$.60.
In the last 3 years, TNXP traded as high as $2,213.76 and as low as $3.21.
The top ETF exchange traded funds that TNXP belongs to (by Net Assets): VTI, VXF, IWM, VTWO, FESM.
TNXP has underperformed the market in the last year with a price return of -81.5% while the SPY ETF gained +12.0%. TNXP has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -73.7% and -39.7%, respectively, while the SPY returned -1.5% and -2.0%, respectively.
TNXP support price is $3.65 and resistance is $4.09 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that TNXP shares will trade within this expected range on the day.